Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Boers

Showing results (91-100 of 123) with videos related to

Pageof 13
Sort By:
BMC Cancer|March 26, 2021
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trialE E A P Mulder, K de Joode, S Litière, et al.
Annals of Internal Medicine|February 15, 2021
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort StudyMonique K van der Kooij, Karijn P M Suijkerbuijk, Maureen J B Aarts, et al.
Cancers|January 21, 2023
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome AnalysisMelissa M De Meza, Willeke A M Blokx, Johannes J Bonenkamp, et al.
Cancers|July 31, 2020
Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and ResponseMonique K van der Kooij, Marjolein J A L Wetzels, Maureen J B Aarts, et al.
ESMO Open|November 17, 2020
Lower risk of severe checkpoint inhibitor toxicity in more advanced diseaseRik J Verheijden, Anne M May, Christian U Blank, et al.
Melanoma Research|June 15, 2022
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitorsRawa K Ismail, Karijn P M Suijkerbuijk, Anthonius de Boer, et al.
Cancers|July 2, 2021
Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint InhibitorsNienke A de Glas, Esther Bastiaannet, Frederiek van den Bos, et al.
International Journal of Cancer|June 26, 2024
Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide studyManja Bloem, Olivier J van Not, Maureen J B Aarts, et al.
Eclinicalmedicine|February 19, 2024
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021Olivier J van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
British Journal of Cancer|April 15, 2025
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysisM Bloem, M M de Meza, A J M van den Eertwegh, et al.
Pageof 13

Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
BMC Cancer|March 26, 2021
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trialE E A P Mulder, K de Joode, S Litière, et al.
Annals of Internal Medicine|February 15, 2021
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort StudyMonique K van der Kooij, Karijn P M Suijkerbuijk, Maureen J B Aarts, et al.
Cancers|January 21, 2023
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome AnalysisMelissa M De Meza, Willeke A M Blokx, Johannes J Bonenkamp, et al.
Cancers|July 31, 2020
Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and ResponseMonique K van der Kooij, Marjolein J A L Wetzels, Maureen J B Aarts, et al.
ESMO Open|November 17, 2020
Lower risk of severe checkpoint inhibitor toxicity in more advanced diseaseRik J Verheijden, Anne M May, Christian U Blank, et al.
Melanoma Research|June 15, 2022
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitorsRawa K Ismail, Karijn P M Suijkerbuijk, Anthonius de Boer, et al.
Cancers|July 2, 2021
Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint InhibitorsNienke A de Glas, Esther Bastiaannet, Frederiek van den Bos, et al.
International Journal of Cancer|June 26, 2024
Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide studyManja Bloem, Olivier J van Not, Maureen J B Aarts, et al.
Eclinicalmedicine|February 19, 2024
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021Olivier J van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
British Journal of Cancer|April 15, 2025
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysisM Bloem, M M de Meza, A J M van den Eertwegh, et al.
Pageof 13